Medicus Pharma (NASDAQ:MDCX) said on Monday it has entered into a letter of intent with Reliant AI Inc to collaborate on the development of an artificial-intelligence-powered data analytics platform aimed at improving the execution of its clinical trials.
The Nasdaq-listed biotechnology company said the proposed platform would integrate Reliant’s generative AI technology with Medicus’ clinical, operational and proprietary datasets to support data-driven decision-making across its development pipeline.
Medicus said the initial focus of the collaboration would be on dynamic clinical-site selection and patient stratification for an upcoming clinical study of Teverelix, a prostate cancer drug candidate acquired through its purchase of UK-based Antev Ltd last year. The Teverelix study is planned to begin in 2026.
Reliant AI is a privately held decision-intelligence company founded by former DeepMind and Google Brain researchers. Its platform automates data-intensive workflows in life sciences research, including literature analysis and predictive modeling.
Under the terms of the letter of intent, the companies plan to structure the collaboration as a one-year, milestone-based services agreement, with Medicus committing up to $200,000 over a 12-month period, subject to the execution of definitive agreements. The letter of intent is non-binding, and there is no assurance that a final agreement will be completed, Medicus said.
“This proposed collaboration reflects an important strategic step of selectively deploying advanced analytics and AI tools to improve the efficiency, quality, and predictability of clinical development,” Medicus CEO Raza Bokhari said in a statement.
Medicus said the proposed platform could later be expanded to support enrollment forecasting, comparative site selection strategies and pharmacodynamic-informed patient stratification, with potential use in a larger late-stage study planned for 2028.
The company is currently running a Phase 2 clinical trial of its SkinJect program, SKNJCT-003, which uses dissolvable doxorubicin-containing microneedle arrays to treat basal cell carcinoma. Medicus said it completed enrollment of 90 patients in the US study in December and expects to report topline results in the first quarter of 2026.
Medicus is also conducting a related Phase 2 study in the UAE and has received regulatory approvals to expand its SkinJect trial into the UK.